Posted by Michael Wonder on 10 Aug 2017
Berinert approved by Health Canada for the treatment of hereditary angioedema in paediatric patients
9 August 2017 - CSL Behring is pleased to announce that on 31 March 2017 Berinert (C1 esterase inhibitor, human) was approved by Heath Canada for paediatric hereditary angioedema.
Berinert is indicated for the treatment of acute abdominal, facial, or laryngeal attacks of hereditary angioedema of moderate to severe intensity in paediatric and adult patients. The safety and efficacy of Berinert for prophylactic therapy has not been established.
